Comparison tool

5-Amino-1MQ vs AOD-9604 side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

5-Amino-1MQAOD-9604

Share this peptide comparison

Property	5-Amino-1MQ	AOD-9604
Category	Weight Loss	Weight Loss
Also known as	5-amino-1-methylquinolinium, NNMT Inhibitor	Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
FDA approved	No	No
Clinical status	Preclinical research; no published human trials reported in the supplied source Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Clinical trials completed without FDA approval; source also reports Sept 2024 FDA Category 2 removal, expected Category 1 reclassification activity in 2026, and GRAS status. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Fat metabolism, cellular energy, body composition	Fat loss, body composition, localized fat reduction
How it works	5-Amino-1MQ is described in the supplied evidence as an inhibitor of NNMT, the enzyme nicotinamide N-methyltransferase. The proposed model is that lowering NNMT activity may affect adipocyte metabolism through nicotinamide, NAD+ and SAM-related pathways, potentially shifting energy handling in fat tissue. The cited mouse work reported increases in intracellular NAD+ and SAM after NNMT inhibition, but the source does not provide human trial confirmation for these effects.	AOD-9604 is described as a modified fragment of human growth hormone designed around the hormone's fat-metabolism region rather than the broader growth-hormone activity profile. The source reports lab and animal findings consistent with increased lipolysis and reduced lipogenesis. It also reports no meaningful IGF-1 increase, no glucose-metabolism harm in reviewed human safety evidence, and no settled receptor explanation, so the mechanism remains proposed rather than confirmed.
Typical dosing	50-75 mg daily · Once daily, morning · 4-6 weeks on, 2-4 weeks off	300 mcg daily · Once daily, usually morning fasted
Research dosing	20 mg/kg/day (mice) · 4-6 weeks (cycling recommended) · Subcutaneous injection or oral	250-500 mcg daily · 12-24 weeks in studies · Subcutaneous injection or oral
Typical duration	4-6 weeks (cycling recommended)	12-24 weeks in studies
Administration	Subcutaneous injection or oral	Subcutaneous injection or oral administration reported in studies
Timing	Morning, fasted With or without food	Morning, fasted Empty-stomach use reported
Evidence level	Preclinical	Clinical Trials
Possible side effects	Mild headache (Reported with initial dosing in the supplied source.) Nausea (Listed as a reported side effect by the source.) Increased alertness or jitteriness (Source-reported; may relate to timing concerns about sleep disruption.) +2 more Insomnia (Listed as rare in the supplied source.) Elevated blood pressure (Listed as rare in the supplied source.)	Generally very well-tolerated (Overall tolerability characterization reported by the source.) Injection-site reactions (Listed by the source as a reported side effect.) Mild headache (Reported as mild in the source.) +4 more Dizziness (Listed by the source as a reported side effect.) Does NOT produce typical HGH side effects (Source-reported absence of typical HGH-like effects; this does not establish individual safety.) No effect on IGF-1 levels (Source reports no IGF-1 increase in reviewed evidence.) GRAS status by expert panel (Reported safety-status item from the source rather than a symptom.)
Research summary	The supplied source highlights preclinical work on small-molecule NNMT inhibitors in diet-induced obese mice. In that work, treated animals reportedly lost about 5% of baseline weight over roughly 11 days, had lower white adipose mass and reduced circulating cholesterol, while food intake did not change. The source characterizes the overall evidence base as animal and cell research and states that published human trials demonstrating fat loss, increased energy expenditure or long-term safety were not available. The source separately cautions that vendor-promoted percentages for human fat loss remain unsupported by clinical trial evidence.	The supplied source presents a mixed evidence picture. It describes supportive cell and animal findings for fat-metabolism effects, then reports roughly six randomized, double-blind, placebo-controlled human trials involving about 900 participants. A cited safety review is summarized as finding good tolerability, no IGF-1 elevation, no glucose-metabolism harm, and no detectable antibodies. However, the source also states that the largest Phase IIb obesity trial did not beat placebo on its main weight-loss endpoint and that Metabolic Pharmaceuticals halted development around 2007.
References	Source Source	Source Source +1 more Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

5-Amino-1MQ

AOD-9604

Category

Weight Loss

Also known as

5-amino-1-methylquinolinium, NNMT Inhibitor

Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

FDA approved

Clinical status

Preclinical research; no published human trials reported in the supplied source

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Clinical trials completed without FDA approval; source also reports Sept 2024 FDA Category 2 removal, expected Category 1 reclassification activity in 2026, and GRAS status.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Fat metabolism, cellular energy, body composition

Fat loss, body composition, localized fat reduction

How it works

5-Amino-1MQ is described in the supplied evidence as an inhibitor of NNMT, the enzyme nicotinamide N-methyltransferase. The proposed model is that lowering NNMT activity may affect adipocyte metabolism through nicotinamide, NAD+ and SAM-related pathways, potentially shifting energy handling in fat tissue. The cited mouse work reported increases in intracellular NAD+ and SAM after NNMT inhibition, but the source does not provide human trial confirmation for these effects.

AOD-9604 is described as a modified fragment of human growth hormone designed around the hormone's fat-metabolism region rather than the broader growth-hormone activity profile. The source reports lab and animal findings consistent with increased lipolysis and reduced lipogenesis. It also reports no meaningful IGF-1 increase, no glucose-metabolism harm in reviewed human safety evidence, and no settled receptor explanation, so the mechanism remains proposed rather than confirmed.

Typical dosing

50-75 mg daily · Once daily, morning · 4-6 weeks on, 2-4 weeks off

300 mcg daily · Once daily, usually morning fasted

Research dosing

20 mg/kg/day (mice) · 4-6 weeks (cycling recommended) · Subcutaneous injection or oral

250-500 mcg daily · 12-24 weeks in studies · Subcutaneous injection or oral

Typical duration

4-6 weeks (cycling recommended)

12-24 weeks in studies

Administration

Subcutaneous injection or oral

Subcutaneous injection or oral administration reported in studies

Timing

Morning, fasted

With or without food

Morning, fasted

Empty-stomach use reported

Evidence level

Preclinical

Clinical Trials

Possible side effects

Mild headache (Reported with initial dosing in the supplied source.)
Nausea (Listed as a reported side effect by the source.)
Increased alertness or jitteriness (Source-reported; may relate to timing concerns about sleep disruption.)

+2 more

Insomnia (Listed as rare in the supplied source.)
Elevated blood pressure (Listed as rare in the supplied source.)

Generally very well-tolerated (Overall tolerability characterization reported by the source.)
Injection-site reactions (Listed by the source as a reported side effect.)
Mild headache (Reported as mild in the source.)

+4 more

Dizziness (Listed by the source as a reported side effect.)
Does NOT produce typical HGH side effects (Source-reported absence of typical HGH-like effects; this does not establish individual safety.)
No effect on IGF-1 levels (Source reports no IGF-1 increase in reviewed evidence.)
GRAS status by expert panel (Reported safety-status item from the source rather than a symptom.)

Research summary

The supplied source highlights preclinical work on small-molecule NNMT inhibitors in diet-induced obese mice. In that work, treated animals reportedly lost about 5% of baseline weight over roughly 11 days, had lower white adipose mass and reduced circulating cholesterol, while food intake did not change. The source characterizes the overall evidence base as animal and cell research and states that published human trials demonstrating fat loss, increased energy expenditure or long-term safety were not available. The source separately cautions that vendor-promoted percentages for human fat loss remain unsupported by clinical trial evidence.

The supplied source presents a mixed evidence picture. It describes supportive cell and animal findings for fat-metabolism effects, then reports roughly six randomized, double-blind, placebo-controlled human trials involving about 900 participants. A cited safety review is summarized as finding good tolerability, no IGF-1 elevation, no glucose-metabolism harm, and no detectable antibodies. However, the source also states that the largest Phase IIb obesity trial did not beat placebo on its main weight-loss endpoint and that Metabolic Pharmaceuticals halted development around 2007.

References

Source Source

+1 more

Source

Full profile

View Details